AUSTAR (06118) saw its gains expand to over 54% in late trading session. As of press time, the stock was up 48.04% to HK$1.51, with trading volume reaching HK$8.4778 million.

According to public information, Hong Kong Austar Group operates as a technology-based pharmaceutical engineering solutions provider. As one of the group's main subsidiaries, Austar Life Sciences Products and Services Division encompasses nine business segments: sterile drug production contamination control consumables, equipment and services; environmental monitoring and detection systems; validation and stand-alone equipment; biological upstream process systems; single-use process systems; laboratory informatization; and life science consulting.

AUSTAR's interim results showed shareholders' attributable profit of HK$24.999 million, representing a year-on-year increase of 325.37%.